Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia-Reference-Cited by-同舟云学术

Cost-Effectiveness of Dolutegravir as a First-Line Treatment Option in the HIV-1–Infected Treatment-Naive Patients in Russia

Published:2018-09 Issue: Volume:16 Page:74-80
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Tremblay Gabriel,Chounta Vasiliki,Piercy James,Holbrook Tim,Garib Shan Ashton,Bukin Evgeny K.,Punekar Yogesh Suresh

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference33 articles.

1. World report: gaps remain in Russia's response to HIV/AIDS;Clark;Lancet,2016

2. Pokrovsky V.V. et al. National guidelines for dispensary observation and treatment of patients with HIV infection. Epidemiology and infectious diseases: current items [in Russian]. 2016; 6 (suppl.):1-72.

3. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study;Raffi;Lancet,2013

4. Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial;Raffi;Lancet Infect Dis,2013

5. Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study;Clotet;Lancet,2014

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative costs and potential affordability of a multifaceted intervention to improve treatment outcomes among people with HIV who inject drugs in Russia: economic evaluation of the LINC‐II randomized controlled trial;Journal of the International AIDS Society;2024-02

2. Cost and cost-effectiveness of dolutegravir-based antiretroviral regimens: an economic evaluation of a clinical trial;AIDS;2021-12-15

3. Cost-Utility Analysis of Dolutegravir- Versus Efavirenz-Based Regimens as a First-Line Treatment in Adult HIV/AIDS Patients in Ethiopia;PharmacoEconomics - Open;2021-06-16

4. The Cost-Effectiveness and Budget Impact of Ibalizumab-uiyk for Adults with Multidrug-Resistant HIV-1 Infection in the United States;PharmacoEconomics;2021-02-03

5. Medication market performance analysis with help of Analytic Hierarchy Processing;Entrepreneurship and Sustainability Issues;2020-09-30